Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy

ClinicoEconomics and Outcomes Research

Volumn 3, Issue 1, 2011, Pages 79-87

  Peng, Xiaomei ^a   Ascher Svanum, Haya ^a   Faries, Douglas E ^a   Stauffer, Virginia L ^a   Kollack Walker, Sara ^a   Kinon, Bruce J ^a   Kane, John M ^b  

^a ELI LILLY AND COMPANY   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Cost beneft analysis; Olanzapine; Risperidone; Schizophrenia; Treatment outcome

Indexed keywords

GENERIC DRUG; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84855591527     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S16859     Document Type: Article

References (27)

1. Lehman AF, Lieberman JA, Dixon LB. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(9):1-56.
2. Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry. 2005;50(13 Suppl 1):S7-S57.
3. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003;160(11):2063-2065.
4. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102(1-3):230-240.
5. Ascher-Svanum H, Nyhuis AW, Faries DE, et al. Clinical, functional, and economic ramifcations of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008;34(6): 1163-1171.
6. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60(12):1228-1235.
7. Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: A hypothesis tested, confrmed and extended. Biol Psychiatry. 2005;57(12):1543-1549.
8. Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsy-chotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010;35(2): 581-590.
9. Kinon BJ, Chen L, Ascher-Svanum H, et al. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia. Schizophr Res. 2010;118(1-3):176-182.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition. New York, NY: American Psychiatric Publishing Inc; 2000.
11. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
12. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) User's Manual. North Tonawanda, NY: Multi-Health Systems Inc; 2000.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology. In: Publication ADM 76-338. Revised. Rockville, MD: US Department of Health, Education, and Welfare; 1976.
14. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. 1st ed. New York, NY: Oxford University Press; 1996.
15. Kane JM, Kim E, Kan HJ, et al. Comparative utility of aripiprazole and haloperidol in schizophrenia: Post hoc analysis of two 52-week, randomized, controlled trials. Appl Health Econ Health Policy. 2009; 7(2):109-119.
16. Lenert LA, Sturley A P, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res. 2004;71(1):155-165.
17. Lenert LA, Sturley A P, Rapaport MH, et al. Corrigendum to "Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores". Schizophr Res. 2005;80(1):135-136.
18. Simpson GM, Angus J W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
19. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
20. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: US National Institute of Health; 1976.
21. Mohr PE, Cheng CM, Claxton K, et al. The heterogeneity of schizophrenia in disease states. Schizophr Res. 2004;71(1):83-95.
22. Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: Symptoms, quality of life and resource use under customary clinical care. Clin Drug Investig. 2004;24(5): 275-286.
23. Analysource Data [Website on the Internet]. AWP Cost of Antipsychot-ics. Available from: http://www.analysource.com. Accessed March 31, 2008.
24. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006; 163(12):2080-2089.
25. Faries D, Leon A, Haro J, Obenchain R. Analysis of Observational Health Care Data Using SAS. Cary, NC: SAS Press; 2010.
26. Obenchain RL, Robinson RL, Swindle RW. Cost-effectiveness inferences from bootstrap quadrant confdence levels: Three degrees of dominance. J Biopharm Stat. 2005;15(3):419-436.
27. Polsky D, Doshi JA, Bauer MS, Glick HA. Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry. 2006; 163(12):2047-2056.